Skip to main content
HCPCS Q2043 · Level II · Part B drug

Q2043: sipuleucel-t (Provenge), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q2043

Billing unit
Per infusion (minimum 50 million cells)
Sipuleucel-t auto cd54+
ASP payment limit
$55,663.131
October 2026; -0.5% vs July 2026
Practitioner MUE
1
MAI 2
OPPS status
SI K
APC 9273
NCCI exposure
1 col-2 pairs
100% allow a modifier
Coverage articles
1
6 states

TL;DR

HCPCS Q2043 is the Level II code for Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion, billed per Per infusion (minimum 50 million cells). The Medicare Part B ASP payment limit for October 2026 is $55,663.131 per billing unit, down 0.5% from July 2026. The practitioner MUE allows up to 1 units per date of service (MAI 2), so a full 1-unit day is $55,663.13 at the current limit. Under OPPS it carries status indicator K in APC 9273. Q2043 is billed in units of Per infusion (minimum 50 million cells); the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 1 NDC to it, sold as Provenge by Dendreon Pharmaceuticals LLC. It is the bundled column-2 code in 1 NCCI pair, most often with 36522. 1 Medicare coverage article lists the code across 6 states, including A55719.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q2043 at $55,663.131 per Per infusion (minimum 50 million cells) for October 2026, derived from manufacturer average sales price plus 6%, compared with $55,932.427 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q2043
QuarterPayment limitPerCoinsurance
October 2026$55,663.131Per infusion (minimum 50 million cells)20%
July 2026$55,932.427Per infusion (minimum 50 million cells)—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to Q2043. Report the NDC in the claim's drug segment and bill the number of Q2043 units that equals the quantity administered divided by Per infusion (minimum 50 million cells); the last column gives units per full package.

NDCs that crosswalk to Q2043
NDCDrug nameLabelerPackage sizeBilling units / package
30237-8900-06ProvengeDendreon Pharmaceuticals LLC250 × 11

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q2043. For practitioners the limit is 1 unit per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for Q2043 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction
Facility outpatient hospital12 Date of Service Edit: PolicyCode Descriptor / CPT Instruction

MUE for Q2043 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

In the practitioner PTP file v323r0 (effective October 1, 2026), Q2043 is the column-2 code in 1 active pair, 100% of which allow a modifier (indicator 1), and the column-1 code in 171. 113 historical pairs have been deleted over time. CMS's most frequent rationale: Mutually exclusive procedures.

When billed with these column-1 codes, Q2043 is the bundled component unless the pair allows a modifier and the documentation supports a distinct service.

Column-1 codes most often paired with Q2043
Column-1 codePairs
36522 (CPT; descriptor licensed by AMA)1

These codes are considered components of Q2043 when reported together on the same date of service.

Column-2 codes most often bundled into Q2043
Column-2 codePairs
0213T (CPT; descriptor licensed by AMA)1
0216T (CPT; descriptor licensed by AMA)1
0596T (CPT; descriptor licensed by AMA)1
0597T (CPT; descriptor licensed by AMA)1
0692T (CPT; descriptor licensed by AMA)1
0903T (CPT; descriptor licensed by AMA)1
0904T (CPT; descriptor licensed by AMA)1
0905T (CPT; descriptor licensed by AMA)1
36000 (CPT; descriptor licensed by AMA)1
36400 (CPT; descriptor licensed by AMA)1

The counts above are exposure, not answers for a specific claim. Check Q2043 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q2043 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists Q2043 in their HCPCS tables, covering 6 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q2043
ArticleTitleContractor(s)StatesRelated LCD
A55719Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – ClarificationNoridian Healthcare Solutions, LLCAZ MT ND SD UT WY—

Diagnoses Medicare contractors cover for Q2043

One billing and coding article attaches a covered diagnosis list to Q2043: 23 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q2043
ICD-10-CMDescription (FY2027)Articles covering
C61Malignant neoplasm of prostate1 of 1
C77.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes1 of 1
C77.2Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes1 of 1
C77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes1 of 1
C77.5Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes1 of 1
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions1 of 1
C77.9Secondary and unspecified malignant neoplasm of lymph node, unspecified1 of 1
C78.00Secondary malignant neoplasm of unspecified lung1 of 1
C78.01Secondary malignant neoplasm of right lung1 of 1
C78.02Secondary malignant neoplasm of left lung1 of 1
C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct1 of 1
C79.00Secondary malignant neoplasm of unspecified kidney and renal pelvis1 of 1
C79.01Secondary malignant neoplasm of right kidney and renal pelvis1 of 1
C79.02Secondary malignant neoplasm of left kidney and renal pelvis1 of 1
C79.10Secondary malignant neoplasm of unspecified urinary organs1 of 1
8 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q2043 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q2043, by article
ArticleContractorGroups that applyCovered codes for Q2043Full list
A55719Noridian Healthcare Solutions, LLCone list for every code in the article23Open the list

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q2043 carries status indicator K and is assigned to APC 9273, with a published national unadjusted payment of $55,663.131. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q2043 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $55,663.13 per Per infusion (minimum 50 million cells), paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q2043 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q2043

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q2043

What does HCPCS code Q2043 describe?

Q2043 is defined by CMS as "Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion". Each billing unit represents Per infusion (minimum 50 million cells), so the units reported on the claim must equal the dose administered divided by that unit.

Is Q2043 a CPT code?

No. Q2043 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as sipuleucel-t (Provenge); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q2043 reports the drug itself in per infusion (minimum 50 million cells) units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q2043 in October 2026?

The ASP-based payment limit is $55,663.131 per Per infusion (minimum 50 million cells), with 20% beneficiary coinsurance. The July 2026 limit was $55,932.427. Commercial payers use their own fee schedules.

How many units of Q2043 can be billed per day?

The practitioner Medically Unlikely Edit is 1 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Code Descriptor / CPT Instruction" as the rationale.

Which NDCs map to Q2043?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Provenge (Dendreon Pharmaceuticals LLC). For example NDC 30237-8900-06 (package size 250) equals 1 billing unit of Q2043.

Does Q2043 have NCCI bundling edits?

In the v323r0 practitioner PTP file, Q2043 appears as the column-2 (bundled) code in 1 active pairs and as the column-1 code in 171. 100% of the column-2 pairs allow a modifier (indicator 1). The most frequent column-1 partners are 36522, and CMS's leading rationale is "Mutually exclusive procedures".

Which Medicare coverage articles mention Q2043?

1 current Billing and Coding Article in the Medicare Coverage Database lists Q2043, covering 6 states: A55719 (Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification).

What diagnosis codes support Q2043?

One Medicare billing and coding article lists 23 covered ICD-10-CM codes for Q2043, for example C61 (Malignant neoplasm of prostate); C77.1 (Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes); C77.2 (Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes); C77.4 (Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes); C77.5 (Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.